Home > Insider Trading > Filing (0001735276-21-000041)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALNY	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1458494	Akshay Vaishnaw	675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142	President, R&D	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-04-19	5,083	$0.00	22,908	No	4	A	Direct
Common Stock	Disposition	2021-04-19	1,678	$136.76	21,230	No	4	S	Direct
Common Stock	Disposition	2021-04-19	989	$137.60	20,241	No	4	S	Direct
Common Stock	Disposition	2021-04-19	622	$138.64	19,619	No	4	S	Direct
Common Stock	Disposition	2021-04-19	417	$140.02	19,202	No	4	S	Direct
Common Stock	Disposition	2021-04-20	2,266	$131.75	16,936	No	4	F	Direct
Common Stock	Disposition	2021-04-20	85	$134.56	16,851	No	4	F	Direct
Common Stock	Disposition	2021-04-21	203	$135.41	16,648	No	4	S	Direct
Common Stock	Disposition	2021-04-21	1,892	$136.84	14,756	No	4	S	Direct
Common Stock	Disposition	2021-04-21	530	$137.60	14,226	No	4	S	Direct
Common Stock	Disposition	2021-04-21	107	$138.48	14,119	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	F	Direct
No	4	F	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	515	Indirect	by Managed Account

Footnotes

On February 26, 2020, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2019 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the first performance criterion was met and one-third of the PSU award vested as of April 19, 2021.
All sales reported on this Form 4, other than the sell-to-cover for taxes on April 20, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021.
Sale prices ranged from $136.21 to $137.17.
Sale prices ranged from $137.28 to $138.13.
Sale prices ranged from $138.34 to $139.27.
Sale prices ranged from $139.72 to $140.18.
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.
Sale prices ranged from $135.24 to $135.96.
Sale prices ranged from $136.41 to $137.33.
Sale prices ranged from $137.42 to $138.10.
Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.